Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Yahoo! Finance
Net Product Sales of LUPKYNIS (Q4 2024): $57.6 million, up 36% from $42.3 million in Q4 2023. Net Product Sales of LUPKYNIS (Full Year 2024): $216.2 million, up 36% from $158.5 million in 2023. Cash Flow from Operations (Q4 2024): $30.1 million compared to $14.3 million in Q4 2023. Cash Flow from Operations (Full Year 2024): $44.4 million compared to cash flow used in operations of $33.5 million in 2023. Cash Equivalents, Restricted Cash, and Investments (End of 2024): $358.5 million. Gross Margin (Q4 2024): 91% compared to 88% in Q4 2023. Gross Margin (Full Year 2024): 88% compared to 92% in 2023. Total Operating Expenses (Q4 2024): $61.5 million compared to $74.8 million in Q4 2023. Total Operating Expenses (Full Year 2024): $239.8 million compared to $267.2 million in 2023. Net Income (Q4 2024): $1.4 million or $0.01 per share compared to a net loss of $26.9 million or $0.19 per share in Q4 2023. Net Income (Full Year 2024): $5.8 million or $0.04 per share comp
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms [Seeking Alpha]Seeking Alpha
- Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Assessing Aurinia Pharmaceuticals After Its 80% 2025 Surge and Lupus Nephritis Momentum [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was given a new $16.00 price target on by analysts at Leerink Partners.MarketBeat
AUPH
Earnings
- 11/4/25 - Beat
AUPH
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- 11/4/25 - Form 8-K
- AUPH's page on the SEC website